Skip to Content
Investing Specialists

A New Pick from Morningstar's Small-Cap Superstars

We highlight one new 5-star stock held by leading small-cap fund managers.

Mentioned: , , , , , , , , ,

As we discussed in previous articles, one of the best and easiest ways to screen for new investment ideas is by monitoring the activity and holdings of successful fund managers. The aim of Morningstar's Small-Cap Superstars is to combine some of the best ideas from our favorite small-cap fund managers with our fellow analysts here at Morningstar.

Deciding which stocks to highlight is simple: First, the stock must have a Morningstar Rating of 5 stars, and second, it must be held by at least a handful of the 25 small-cap fund managers on our watch list (see below). We also consider the size of the holding in the respective funds as a way to further refine our selection process. After running our screens and analyzing the respective merits of the Superstars' holdings, we'd like to highlight our latest pick,  Markel Corporation (MKL) (which is technically a mid-cap company, with a market capitalization of $3.6 billion).

Markel
According to Morningstar equities strategist Justin Fuller, Markel's strong underwriting and disciplined investment approach garner this insurer a narrow moat. The firm's underwriters focus on developing expertise in specialty insurance products that are too small or too difficult for larger rivals to underwrite. This helps to avoid fierce pricing competition. Fuller also likes the fact that Markel's underwriters' total compensation is contingent on the product generating underwriting profit, which means underwriters are compelled to refuse business that doesn't meet the firm's rigid pricing criteria. The company generates significant float (temporary cash holdings that accrue because premiums are received well in advance of claim payment), which it invests to boost shareholder returns. The firm has a successful long-term track record in public equity investments and has started making private-equity investments as well, a move that Fuller endorses. Risks for the company include the prospect of management overpaying for a large insurance acquisition, exposure to asbestos claims, and increased competition from Bermuda startups.

John Owens does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.